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ABSTRACT   Background: 5-HT4 agonists (mosapride) and acetylcholine esterase inhibitor 
(acotiamide) are prokinetics used to treat functional dyspepsia (FD). However, to date, there 
has been no direct comparative study between them. The aim of this study was to compare the 
drugs’ efficacy and safety and to determine their predictive biomarkers.
   Methods: The present study was a prospective, randomized, open-labeled, and crossover 
trial in Japanese FD patients. FD was diagnosed using Rome IV. We performed upper 
gastrointestinal (GI) endoscopy, GI symptom rating scale, and 8-item Short-Form Health Survey 
to evaluate the presence of GI disorders, GI symptoms, and quality of life (QOL), respectively. 
Responders were defined when reporting at least a 40% improvement of the GSRS scores from 
their baseline.
   Results: In total, 60 Japanese FD patients were randomly assigned to the acotiamide 
preceding group (n = 30) or mosapride preceding group (n = 30), and 51 patients were finally 
analyzed. Following treatment with both mosapride and acotiamide, GI symptoms and QOL 
scores improved significantly. The responder rates of mosapride and acotiamide were 37% and 
33%, respectively. No severe adverse clinical event developed. The prevalence of H. pylori  
eradication history was significantly lower in the mosapride responder group than in the non-
responder group (45.9% vs. 14.2%,  p  = 0.03).
   Discussion: Mosapride and acotiamide had similar effects on GI symptoms in FD patients 
in the absence of severe adverse events. H. pylori  infection might impact in the pathogenesis 
of functional dyspepsia. Further investigation is needed to clarify the difference between 
mosapride and acotiamide. doi：10.11482/KMJ-E201945015　(Accepted on May 28, 2019)
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〈Regular Article〉
enhances gastrointestinal (GI) motility. They are 
predominantly prescribed for functional GI disorders 
INTRODUCTION
    Prokinetic agents are a drug category that 
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(FGIDs) and functionally derived symptoms such as 
abdominal discomfort, bloating, and constipation１）. 
Functional dyspepsia (FD) is among the most 
recognized FGIDs and target of prokinetic agents. 
FD patients tend to have postprandial fullness, early 
satiation, epigastric pain, and epigastric burning 
in the absence of abnormal findings after routine 
evaluations２）. FD’s pathogenesis includes gastric 
dysmotility. Therefore, prokinetics represent one of 
the key therapeutic options for FD patients３）.
   Mosapride is a derivative of benzamide and 
selective serotonin type 4  (5-HT4) receptor 
agonist ４）. Unlike other 5-HT4 receptor agonists 
such as cisapride, it has little effect on the K+ 
channel. Consequently, it causes QT prolongation 
and cardiovascular events５）. It is known that the 
5-HT4 receptor plays a key role in gastric motility 
such as gastric emptying. Therefore, mosapride has 
been primarily used as a treatment for FD patients 
in Japan and other Asian countries６）. A previous 
multi-center study for Japanese FD patients reported 
adequate efficacy and safety of mosapride７）. On 
the contrary, in a meta-analysis on FD patients in 
Eastern and Western countries, no significant effect 
due to mosapride was observed８）.
   Acotiamide inhibits acetylcholine esterase (AchE) 
and blocks M1 and M2 muscarinic receptors, 
resulting in acetylcholine release enhancement at 
the neuromuscular junction９，10）. Various placebo-
controlled trials have demonstrated significant 
efficacy of acotiamide on clinical symptoms and 
gastric motility in Japanese FD patients (e.g., 
accommodation and gastric emptying)11－13）. Of 
note, GI symptoms long-term safety and clinical 
improvement in FD patients were also confirmed in 
European countries14）.
   Based on these results, prokinetics such as 
acotiamide and mosapride represent front-line 
therapy in Japanese clinical guidelines for FD 
patients15）. Although only acotiamide is covered 
by Japanese national insurance, other prokinetics 
in particular mosapride are stil l  frequentry 
selected16）. The choice of prokinetics is based on 
the physicians’ preferences. This is due to the fact 
that to date, no direct head-to-head comparative 
trial between prokinetics has been conducted. 
Furthermore, little is known about predicting factors 
for the effectiveness of prokinetics. However, it has 
been reported that atrophic gastritis has been related 
to the effectiveness of acotiamide17）.
   The purposes of this study were to compare 
the efficacy and safety between mosapride and 
acotiamide for FD patients and to investigate 
biomarkers to predict the effectiveness of both 
medicines.
SUBJECTS AND METHODS
   This study was a prospective, randomized, open-
labeled, and crossover trial conducted in Kawasaki 
Medical School. The study was performed between 
December 2016 and February 2018. The ethical 
committee approved this trial (IRB No.2584). 
Additionally, the trial was registered in the 
University Hospital Medical Information Network 
Clinical Trials Registry (UMIN000024049). 
Written informed consent was obtained from all the 
participants.
Subjects
   Patients with FD and irritable bowel syndrome 
(IBS) were diagnosed and subtyped according to 
the Rome IV criteria18，19）. Gastroesophageal reflux 
disease (GERD) was diagnosed based on reflux-
related symptoms or by means of endoscopic 
findings of esophagitis20）. With reference to the 
Rome IV criteria, we excluded patients based 
on the following characteristics: the presence of 
Helicobacter pylori infection, any malignant disease, 
ulcerative disease, systemic inflammatory diseases, 
>85 years old or <15 years of age. Furthermore, 
we excluded from the study patients with a history 
of treatment with mosapride or acotiamide within 
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a year, hypersensitivity to both medicines, various 
diseases affecting GI motility (e.g., severe diabetes, 
severe mental disorders, and Parkinson disease).
Endoscopic examination and h. pylori infection
   All patients underwent an upper GI endoscopy 
before treatment. Reflux esophagitis (RE) was 
diagnosed and classified using the Los Angeles 
Classification20）. Atrophic gastritis was assessed 
based on the Kimura–Takemoto classification21）. 
Specifically, we classified the closed type as mild 
atrophic gastritis (C1–C3) and the open type as 
severe atrophic gastritis (O1–O3).
    The status of negative H. pylori infection was 
determined through a less than the cut-off value of 
serum IgG antibodies (E plate test, Eiken Kagaku, 
Inc., Toyo Japan) or 13C-Urea breath test.
Treatment randomization
   We performed a prospective, randomized, open-
labeled, and crossover trial comparing mosapride 
and acotiamide. Patients received mosapride, 5 
mg three times/day７）, or acotiamide, 100 mg three 
times/day13）. Patient selection was based on a 
computer-generated randomization code. Individuals 
were administered each medicine and vice versa 
after the 2 weeks of treatment. Fig. 1 summarizes 
the trial flow.
Study endpoints and outcome measurements
   The GI symptom rating scale (GSRS) is composed 
of 15 questions. These generate five components 
including GERD, abdominal pain, indigestion, 
diarrhea, and constipation. Each item was rated 
according to severity, on a scale from 1 (no 
discomfort at all) to 7 (very severe discomfort)22）. 
An 8-item Short-Form Health Survey (SF-8; 
Japanese translation) was used to evaluate the 
quality of life (QOL) scores23）. The questionnaires 
were answered before and after each administration. 
Patients were defined as responders when reporting 
at least a 40% improvement of the GSRS scores 
from their baseline24）. We set the primary endpoint 
to be the comparison of acotiamide and mosapride’
s effects based on the GSRS scores. Secondary 
endpoints were to compare adverse events and 
to investigate the predictive clinical factors for 
responders.
Acotiamide 100mg 3times/day
Mosapride 5mg  3times/day
Randomization
Blood sampling
Quastionarie
Quastionarie Quastionarie
Treatment period (4 weeks) Baseline period (1‐8weeks)
Visit Visit Visit
No prokinetics
Endoscopy
Mosapride 5mg  3times/day
Acotiamide 100mg 3times/day
Figure 1
Fig. 1. Patients flow. After enrollment, patients received upper endoscopy and blood sampling prior to 
treatment. Subjects were treated for a total of 4 weeks. Half of them were treated with acotiamide and 
the remaining were given mosapride as an initial treatment, for 2 weeks. Following the initial 2 weeks of 
treatment, patients were administered the other medication for 2 weeks. Questionnaires were performed at 
baseline, then after 2 and 4 weeks.
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Statistical analysis
   We calculated the appropriate sample size to be at 
least 47 patients, based on earlier studies13，25）. We 
set α as 0.05 and 1-βas 0.803. We showed in mean 
and standard deviation continuous and distributed 
data including the following: age, body mass index, 
and GSRS scores. We presented in percentage the 
categorical data such as sex, prevalence of GERD, 
or IBS. We performed comparisons between two 
groups by using chi-square test (frequencies), student 
t-test (distributed continuous variables), and paired 
t-test. We considered as statistically significant 
a p-Value < 0.05. Statistical computations were 
processed using the SPSS statistical software 
(version 24.0; IBM Corp, Armonk, NY, USA).
 
RESULTS
Enrollment and baseline characteristics
   We enrolled 64 patients with a suspected diagnosis 
of FD. Of these, 4 patients were excluded prior 
to treatment because of the following reasons: 
unwillingness for treatment, gastric cancer, and H. 
pylori infection. The remaining 60 patients were 
randomly assigned to the acotiamide preceding 
group (n = 30) or mosapride preceding group (n 
= 30). A total of 9 patients have not completed 
protocol due to: adverse events (n = 1), withdrawal 
(n = 1), or missing data (n = 7). Therefore, 51 
patients were finally analyzed (Fig. 2). Table 1 
shows demographics and the clinical characteristics 
at the base line. No significant difference was 
observed between the two groups.
Comparison of improvement in GI symptom and 
QOL scores
   Both medicines were similarly effective, indicating 
significant improvement, except for diarrhea scores, 
after 2 weeks of treatment from baseline scores 
(Fig. 3, Table 2). Similar improvements were 
observed between the mosapride preceding group 
(from 2.53 to 2.01, p < 0.01) and the acotiamide 
preceding group (from 2.87 to 2.14, p = 0.01). 
The improvements were maintained 2 weeks after 
switching the medicine. Additionally, we found that 
Randomized (n=60)
Acotiamide preceding group(n=30) Mosapride preceding group(n=30)
Completed and analyzed (n=24) Completed and analyzed (n=27)
Assesed for eligibility 
(n=64)
Excluded (n=4)
Unwillingness
H.pylori infection
gastric cancer 
Lost to 
follow‐up
(n=3)
Lost to
follow‐up
(n=6) Allocated to acotiamide
Allocated to mosapride
Allocated to mosapride 2 weeks
4 weeks
Allocated to acotiamide
Figure 2
Fig. 2. Flow diagram. Eligibility was assessed in 64 FD patients. Of those patients, 4 were excluded and 60 were 
randomly treated with acotiamide or mosapride. Finally, 51 patients were analyzed.
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Table 1. Comparison of demographic, clinical and serological characteristics at baseline between mosapride and acotiamide preceding 
group
Variables Mosaprido precedinggroup (n = 27)
Acotiamido preceding
group (n = 24) p
Age mean (SD) 55.1 (20.7) 51.5 (18.6) 0.31a
Sex men (%) 6 (22.2) 7 (29.1) 0.74b
BMI mean (SD) 21.9 (3.3) 24.1 (5.2) 0.11a
Subtypes
     PDS (%) 14 (51.8) 10 (41.7)
0.74b     EPS (%) 9 (33.3) 9 (37.5)
     Overlap (%) 4 (14.8) 5 (20.8)
GERD (%) 14 (51.9) 14 (58.3) 0.40b
     RE (%) 5 (18.5) 4 (16.7) 0.58b
IBS 11 (40.7) 7 (29.1)
     IBS-C 11 (40.7) 6 (25.0)
0.31b
     IBS-D 0 (0) 1 (4.1)
H.pylori eradication (%) 10 (37.0) 10 (41.7) 0.77b
Atrophic gastritis (%) 14 (51.8) 12 (50.0) 0.98b
     Mild 9 (33.3) 8 (29.6)
     Severe 5 (18.5) 4 (16.7)
Anti-acids users (%) 7 (25.9) 7 (29.1) 0.79b
SD, standard deviation; BMI, body mass index; PDS, postprandial distress syndrome; EPS, epigastric pain syndrome; 
GERD, gastroesophageal reflux disease; RE, reflux esophagitis; IBS-D, irritable bowel syndrome; IBS-C, irritable bowel syndrome 
with constipation; IBS-D, irritable bowel syndrome with diarrhea; GSRS, gastrointestinal symptom rating scale; SF-8, Short Form-8.
p value was calculated by the student T-test(a), Chi-squared test (b).
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Fig. 3. GSRS scored over the trial period. Scores are expressed as mean. A significant difference 
was observed between baseline and post-medication scores. ＊ p < 0.05.
GSRS, gastrointestinal symptom rating scale; SF-8, Short Form-8
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improvement of GSRS sub-scores and SF-8 scores 
were similar between both medicines (Table 2).
Safety
   In 6 patients, several clinical adverse events were 
reported during medication (Table 3). Respectively, 
nausea and heartburn occurred in each patient 
taking mosapride. Nausea and heartburn occurred 
in one of each patient and diarrhea developed in 
both cases taking acotiamide. Of note, all symptoms 
were mild and no serious adverse event requiring 
hospitalization was observed.
Comparison between responder and non-responder 
on mosapride and acotiamide treatment
   The prevalence of H. pylori eradication history 
was significantly lower in the mosapride responder 
group than in the non-responder group considering 
total GSRS scores (45.9% vs. 14.2%, p = 0.03). 
However, no other clinical factors associated with 
the responder of each treatment were found (Table 
4). 
 
DISCUSSION
   Our study demonstrates that efficacy and safety 
do not differ between mosapride and acotiamide 
for Japanese FD patients. To the best of our 
knowledge, this is the first clinical comparative 
trial between acotiamide and other prokinetics in 
FD patients. There have been earlier studies on 
the efficacy of acotiamide vs. placebo effect12）. 
However, to date, there has been no published 
study indicating mosapride’s effects attenuating 
GI symptoms vs. placebo effect８）. Contrary to our 
expectations, we did not confirm a difference in 
the effectiveness of either of the two drugs for FD 
symptoms. FD has heterogeneous pathophysiology. 
It includes symptoms such as abnormal gastric 
motility, hypersensitivity for extension or acid 
stimuli, and mental impairment including anxiety or 
depression２）. Earlier studies have shown that both 
mosapride and acotiamide improve gastric emptying 
and accommodation６，11）. Both drugs have shown 
to improve reflux symptoms through increasing 
esophageal motility26，27）.  In our trial, reflux 
Table 2. Score shift of GSRS and SF-8 after treatment 
Score mean (SD)
Mosapride preceding group Acotiamide preceding group
Baseline 2 weeks 4 weeks Baseline 2 weeks 4 weeks
GSRS Total 2.53 (0.8) 2.01 (0.6)* 2.09 (0.9)# 2.87 (0.9) 2.14 (0.6)* 2.18 (0.8)#
     Reflux 2.6 (1.2) 2.2 (0.9)* 2.3 (1.1)# 3.3 (1.3) 2.4 (1.2)* 2.5 (1.6)
     Abdominal pain 2.9 (1.1) 2.0 (0.9)* 1.9 (1.1)# 3.2 (1.3) 2.3 (0.8)* 2.1 (1.2)#
     Indigestion 2.7 (1.1) 2.0 (0.6)* 2.0 (0.7)# 2.7 (1.1) 2.0 (0.6)* 2.0 (0.7)#
     Diarrhea 1.8 (0.8) 1.5 (0.6) 1.6 (0.8) 2.4 (1.3) 2.0 (1.4) 1.9 (0.9)
     Constipation 2.8 (1.4) 2.0 (0.9)* 2.2 (1.0) 2.8 (1.4) 2.0 (0.9)* 2.2 (1.0)
SF-8 total (SD) 20.4 (6.3) 17.3 (7.1)* 17.0 (5.8)# 23.0 (6.1) 19.8 (6.4)* 18.4 (7.1)#
SD, standard deviation; GSRS, gastrointestinal symptom rating scale; SF-8, Short Form-8. p value was calculated by the paired T-test.
*: p < 0.05 Baseline vs. 2 weeks. #: p < 0.05 Baseline vs. 4 weeks
Table 3. Clinical adverse event during treatment period
Adverse event
Mosaprido preceding group(n = 30) Acotiamido preceding group(n = 30)
Mosaprido
(N = 30)
Acotiamido
(N = 27)
Mosaprido
(N = 25)
Acotiamido
(N = 30)
Nausea (%) 1 (3.3) 1 (3.7) 0 (0) 0 (0)
Vomiting (%) 0 (0) 0 (0) 0 (0) 0 (0)
Heartburn (%) 0 (0) 0 (0) 1 (4.0) 1 (3.3)
Diarrhea (%) 0 (0) 1 (3.7) 0 (0) 1 (3.3)
Skin rash (%) 0 (0) 0 (0) 0 (0) 0 (0)
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symptoms were improved after each treatment. 
Furthermore, both drugs were previously reported 
to be effective for treatment of hypersensitivity. Of 
note, mosapride attenuated visceral hypersensitivity 
in acetic acid- or zymosan-induced animal 
model28）. Tack et al.29） clarified that acotiamide 
ameliorated hypersensitivity to distension in a 
human gastric barostat study. We confirmed that 
abdominal pain scores were significantly decreased 
by oral administration of both drugs. The declined 
hypersensitivity and improvement of constipation 
might result in these improved scores of abdominal 
pain. Although racial effects should be carefully 
considered, at least for Japanese FD patients, 
both past studies６，７） and our results suggest that 
mosapride and acotiamide have similar effects in 
improving GI symptoms.
   Regarding QOL, FD patients have impaired 
QOL and social problems30）. It is known that GI 
and psychiatric symptoms influence each other 
bi-directionally, through the brain–gut axis31）. 
Indeed, the improvement of GI symptoms brings 
recovery to mental malaise32）. It has been shown 
that mosapride７） and acotiamide have positive 
therapeutic effects on QOL, evaluated through 
Hospital Anxiety and Depression scale anxiety 
score13）.  Similar to past studies, our results 
demonstrate that both drugs improved patients’ 
QOL as evaluated by using SF-8.
   In terms of safety, in accordance with our results, 
past reports have shown mild adverse events 
including diarrhea during mosapride and acotiamide 
Table 4. Comparison of demographic and clinical characteristics between responder and non-responder on mosapride and acotiamide using 
total GSRS score
Variables
Mosaprido
p
Acotiamido
pNon-Responder
(n = 37)
Responder
(n = 14)
Non-Responder
(n = 38)
Responder
(n = 13)
Age mean (SD) 52.9 (19.7) 54.7 (20.2) 0.77a 53.7 (20.0) 52.4 (19.3) 0.83a
Sex men (%) 7 (17.9) 2 (14.2) 0.70b 9 (23.6) 4 (30.7) 0.61ｂ
BMI mean (SD) 22.7 (4.1) 23.6 (5.6) 0.65a 22.3 (4.1) 25.4 (4.8) 0.11a
Subtypes
     PDS (%) 16 (43.2) 8 (57.1)
0.67ｂ
18 (47.3) 6 (46.1)
0.95ｂ     EPS (%) 14 (37.8) 4 (28.4) 13 (34.2) 5 (38.4)
     Overlap (%) 7 (17.9) 2 (14.2) 7 (18.4) 2 (15.4)
GERD (%) 20 (54.1) 8 (57.1) 0.84ｂ 20 (52.6) 8 (61.5) 0.57ｂ
     RE (%) 7 (17.9) 2 (14.2) 0.69ｂ 6 (15.7) 3 (23.0) 0.55ｂ
IBS 12 (32.4) 6 (46.1) 13 (34.2) 5 (38.4)
     IBS-C 11 (29.7) 6 (46.1)
0.58ｂ
12 (31.5) 5 (38.4)
0.77ｂ
     IBS-D 1 (2.7) 0 (0) 1 (2.6) 0 (0)
H.pylori eradication (%) 17 (45.9) 2 (14.2) 0.03ｂ 16 (42.1) 3 (23.1) 0.19ｂ
Atrophic gastritis (%) 21 (56.7) 5 (35.7) 20 (52.6) 6 (46.1)
     Mild 13 (35.1) 4 (28.4)
0.32ｂ
12 (31.5) 5 (38.4)
0.55ｂ
     Severe 8 (21.6) 1 (7.1) 8 (21.1) 1 (7.6)
Antacids (%) 12 (32.4) 2 (14.2) 0.19ｂ 11 (28.9) 3 (23.1) 0.68ｂ
GSRS Total mean (SD) 2.62 (0.7) 2.87 (1.1) 0.35a 2.61 (0.7) 2.95 (1.0) 0.20a
     Reflux 2.8 (1.2) 3.1 (1.3) 0.57a 2.8 (1.2) 3.1 (1.4) 0.52a
     Abdominal pain 2.9 (1.0) 3.3 (1.4) 0.26a 3.0 (1.1) 3.3 (1.3) 0.40a
     Indigestion 2.6 (0.9) 3.0 (1.6) 0.27a 2.6 (1.0) 3.1 (1.4) 0.16a
     Diarrhea 2.1 (1.0) 2.2 (1.2) 0.78a 2.0 (1.0) 2.3 (1.2) 0.34a
     Constipation 2.8 (1.4) 2.6 (1.4) 0.76a 2.7 (1.4) 2.7 (1.3) 0.99a
SF-8  mean (SD) 21.7 (6.4) 21.3 (6.0) 0.84a 21.1 (6.4) 22.9 (6.0) 0.41a
SD, standard deviation; BMI, body mass index; PDS, postprandial distress syndrome; EPS, epigastric pain syndrome; GERD, 
gastroesophageal reflux disease; RE, reflux esophagitis; IBS-D, irritable bowel syndrome; IBS-C, irritable bowel syndrome with 
constipation; IBS-D, irritable bowel syndrome with diarrhea GSRS, gastrointestinal symptom rating scale; SF-8, Short Form-8; p value was 
calculated by the student T-test(a), Chi-squared test (b).
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treatment11，12，33）. Nausea occurred in one patient, 
who had moderate nausea at baseline, and worsened 
during both mosapride and acotiamide medication 
periods. Therefore, we believe that nausea might 
originate from the disease progression rather than 
the side effects of the drugs.
   Interestingly, we additionally observed that a 
history of H. pylori eradication was associated 
with the efficacy of mosapride. Of note, we found 
that the prevalence of H. pylori eradication history 
was lower in the mosapride responders. Recovery 
of esophagitis and dyspeptic syndrome due to 
gastric acid secretion can occur following H. pylori 
eradication34，35）. Such patients should be treated 
mainly by antacids rather than prokinetics. In the 
present trial, patients were not treated with antacids 
and checking intra-gastric acidity and gastric 
emptying. Mosapride improves GERD symptoms27）. 
Thus, mosapride could be effective for improving 
GERD scores of GSRS in patients with history 
of H. pylori eradication. Taking data from past 
studies and ours together, there may be different 
pathogenesis between post-H. pylori infectious FD 
and FD without any history of H. pylori infection. 
Actually, composition of microbiome in post-H. 
pylori infectious FD and FD without any history of 
H. pylori infection were reported to be different36）. 
A more detailed trial should be performed in order 
to elucidate the relationship between H. pylori 
eradication and the efficacy of mosapride. 
   Our study has some limitations. This trial was 
an open-labeled and not blind trial containing 
possibility of placebo effects and selection bias. To 
minimize subject-expectancy effect and bias, we 
endeavored a crossover design including sufficient 
individuals only in the initial treatment (at least 24 
patients in each treatment). Since our aim was to 
compare the efficacy between the two medicines, 
we designed the trial as an active control trial rather 
than a placebo-controlled one. Moreover, half of the 
total number of subjects enrolled in this study had 
the first contact with the gastroenterology center, 
and the demographics and clinical characteristics of 
the enrolled patients matched previously reported 
epidemiological data on Japanese FD patients37）. 
Thus, we believe that the evidence presented here 
is adoptive and meaningful for Japanese clinical 
practices. Difference of races affects pathogenesis 
and eff icacy of  t reatment  for  FD patients . 
Nevertheless, this single race study provides 
reasonable evidence as an initial step. Another 
limitation is lacking washout period between 
the treatments, and carry-over effect should be 
considered. However, the drugs’ half-life times are 
sufficiently short38，39）, and some patients’ symptoms 
deteriorated following the second phase indicating 
that drug efficacy did not always carry over. 
Moreover, the treatment periods was only two weeks 
and might be too short to evaluate the efficacy. 
However, we detected significant improvement of 
GI symptoms after two weeks, and past multi-center 
trial adopted two weeks as treatment periods７）. 
Lastly, evaluation of GI symptoms was based on 
subjective data, and additional studies investigating 
other measurements such as ultrasonography, gastric 
scintigraphy, pH-impedance, and high-resolution 
manometry are needed to reveal the mechanisms 
of prokinetics at the basis of the efficacy. However, 
our measurements and endpoints were clinically 
relevant, as the most important target of FGIDs 
is the patient’s subjective and self-reported 
outcomes40）. 
   In conclusions, our study demonstrated that 
mosapride and acotiamide were both effective and 
tolerated in FD patients without significant side 
effects. History of H. pylori infection was linked 
with the improvement of GI symptoms by taking 
mosapride. Further studies with an increased 
number of subjects are required in order to confirm 
the results.
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